Abstract: The present invention relates to pharmaceutical compositions for treating blood cancer, which includes 4?-thio-5-aza-2?-deoxycytidine (Aza-T-dCyd), and methods of treating blood cancer using a composition for oral administration that includes Aza-T-dCyd. The present invention provides a significant blood cancer therapeutic effect without having toxicity in a blood cancer mouse model or a human even with the Aza-T-dCyd dose conventionally known to have toxicity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
April 22, 2021
Date of Patent:
January 28, 2025
Assignees:
Southern Research Institute, Pinotbio, Inc.
Inventors:
Mark J. Suto, Rebecca Boohaker, Doo Young Jung, Jin Soo Lee, Hyunyong Cho
Abstract: Provided herein are a linker compound, a linker-drug conjugate where the linker compound is conjugated to a drug, an antibody-drug conjugate where a drug is conjugated to an antibody or an antigen binding fragment thereof via the linker compound, and a method for treating cancer by administering the antibody-drug conjugate to a subject in need thereof.
Type:
Application
Filed:
February 9, 2024
Publication date:
September 5, 2024
Applicant:
PINOTBIO, INC.
Inventors:
Doo Young JUNG, Hyun Yong Cho, Gangadhar Rao Mathi
Abstract: Ophthalmic therapeutic agents having as pharmaceutically active ingredient a poorly water soluble drug of formula 1 are described. Specifically, an ophthalmic formulation containing an inclusion complex of a poorly soluble drug of formula 1 enclosed in cyclodextrin or a cyclodextrin derivative in an aqueous solution of pH 10 or higher is administered to a patient in need of optic nerve protection.
Type:
Application
Filed:
April 28, 2023
Publication date:
April 4, 2024
Applicants:
PINOTBIO, INC., AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Inventors:
Young-joon Park, Sang-won Jeon, Ju-yeong Kim, Jin-soo Lee, Hyun-yong Cho
Abstract: The present disclosure provides crystalline polymorphs of 5-aza-4?-thio-2?-deoxycytidine. The crystalline polymorphs may be formulated in a pharmaceutical composition, optionally in combination with an additional chemotherapeutic agent. The crystalline polymorphs are useful to treat various diseases including blood cancers, such as myelodysplastic syndrome and leukemia. A process for preparing the crystalline polymorphs of 5-aza-4?-thio-2?-deoxycytidine is also disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
July 23, 2021
Date of Patent:
September 20, 2022
Assignees:
PINOTBIO, INC., SOUTHERN RESEARCH INSTITUTE
Inventors:
Mark J. Suto, Doo Young Jung, Jin Soo Lee, Hyunyong Cho